Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een observationeel onderzoek om meer te leren over de veiligheid van Darolutamide bij mannen met prostaatkanker in Korea

4 november 2026 bijgewerkt door: Bayer

Post-marketing surveillanceonderzoek voor goedgekeurd gebruik van darolutamide bij Koreaanse patiënten

This is an observational study in which participants receive a treatment which is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). nmCRPC is a prostate cancer that has not yet spread to other parts of the body and does not respond to lowering testosterone in the body. mHSPC is a prostate cancer that has spread to other parts of the body and can be treated by lowering testosterone levels.

This study looks at the safety of the study drug, darolutamide, in Korean patients with nmCRPC or mHSPC. Darolutamide is currently available for doctors to prescribe to men with nmCRPC or mHSPC. It works by attaching to the special molecules called androgen receptors (AR) within prostate cells and blocks hormones called androgens from attaching to AR, which helps delay cancer growth.

To learn more about the safety of Darolutamide, the researchers will study whether the participants have adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The researchers will also learn more about how well darolutamide is working in these participants.

During this study, the researchers will collect information from the medical records of patients who have been prescribed darolutamide by their doctors.

Each participant will be in this study for 1 year. The whole study will last about 6 years. During this time, the participants will visit their doctor every 2 to 4 months as part of their usual care. At these visits, the doctors will do scans to check the patients' cancer and take blood samples. The patients will answer questions about any medications they are taking and whether they have any adverse events.

Studie Overzicht

Studietype

Observationeel

Inschrijving (Geschat)

600

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Many Locations, Zuid -Korea
        • Werving
        • Many locations

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

19 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Mannelijk

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Patients who have been prescribed Darolutamide for a medically appropriate use will be eligible to be enrolled.

Beschrijving

Inclusion Criteria:

  • Male aged ≥19 years

  • Patients with high risk nmCPRC

    • Castrate level of serum testosterone (< 1.7 nmol/l [50 ng/dL])
    • PSA doubling time < 10 months
  • Patients with mHSPC

    • histologically or cytologically confirmed prostate cancer, and metastases detected on bone scanning, contrast-enhanced computed tomography (CT), or magnetic resonance imaging (MRI).
    • be candidates for androgen-deprivation therapy with/without docetaxel.
  • Patients for whom the decision to initiate treatment with Darolutamide as a first time was made as per investigator's routine treatment practice

  • Written informed consent from subject or legal representative; assent from subject when appropriate

Exclusion Criteria:

  • Patients participating in an investigational program with interventions outside of routine clinical practice
  • Participants with contraindication according to the locally approved prescribing information

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Male patients with nmCRPC or mHSPC

Male patients with a diagnosis of non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) will be enrolled after the decision for treatment with Darolutamide has been made by the investigator.

The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number, severity of adverse events (including SAEs)
Tijdsspanne: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

SAE stands for serious adverse event. An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
Number, severity of adverse drug reactions (including SADRs)
Tijdsspanne: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

SADR stands for serious adverse drug reaction. An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
The outcome of (serious) adverse events
Tijdsspanne: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
The outcome of (serious) adverse drug reactions
Tijdsspanne: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide.

From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Redenen om Darolutamide te beëindigen
Tijdsspanne: Tot 52 weken
Tot 52 weken
Dosering en dosisaanpassing van Darolutamide
Tijdsspanne: Tot 52 weken
Tot 52 weken
Metastasis-free survival (MFS) by nmCRPC indication
Tijdsspanne: Up to 52 weeks

MFS is defined as the time (months) from the initiation of Darolutamide treatment to the date of first observed metastasis.

Up to 52 weeks
Time to first symptomatic skeletal event (SSE) by nmCRPC indication
Tijdsspanne: Up to 52 weeks

Time to SSE is defined as the time (months) from the initiation of Darolutamide treatment to the date of first diagnosed skeletal-related event.

Up to 52 weeks
Time to prostate-specific antigen (PSA) progression by nmCRPC indication
Tijdsspanne: Up to 52 weeks

Time to PSA progression is defined as the time (months) from the initiation of Darolutamide treatment to the date at which PSA is recorded at ≥25% increase above the nadir (lowest screening or baseline) value along with an increase in absolute value of ≥2 ng/mL above nadir.

Up to 52 weeks
Overall survival by nmCRPC indication
Tijdsspanne: Up to 52 weeks

Overall survival is defined as the time (months) from the initiation of Darolutamide treatment until death from any cause.

Up to 52 weeks
Time to Castration-Resistant Prostate Cancer (CRPC) by mHSPC indication
Tijdsspanne: Up to 52 weeks

Time to mCRPC, defined as the time to PSA progression with serum testosterone being at castrate level <0.50 ng/mL, or the time to progression by soft tissue/visceral lesions or time to progression by bone lesions, whatever comes first.

Up to 52 weeks
Time to first symptomatic skeletal event (SSE) by mHSPC indication
Tijdsspanne: Up to 52 weeks

Time to SSE is defined as the time (months) from the initiation of Darolutamide treatment to the date of first diagnosed skeletal-related event.

Up to 52 weeks
Time to prostate-specific antigen (PSA) progression by mHSPC indication
Tijdsspanne: Up to 52 weeks

Time to PSA progression is defined as the time (months) from the initiation of Darolutamide treatment to the date at which PSA is recorded at ≥25% increase above the nadir (lowest screening or baseline) value along with an increase in absolute value of ≥2 ng/mL above nadir.

Up to 52 weeks
Overall survival by mHSPC indication
Tijdsspanne: Up to 52 weeks

Overall survival is defined as the time (months) from the initiation of Darolutamide treatment until death from any cause.

Up to 52 weeks
Time to initiation of subsequent anti-cancer therapy by mHSPC indication
Tijdsspanne: Up to 52 weeks

Time to initiation of subsequent anti-cancer therapy is defined as the time (months) from the initiation of Darolutamide treatment to the date of first administration of any subsequent anti-cancer therapy after discontinuation of Darolutamide.

Up to 52 weeks
Radiological progression (Soft tissue/ Bone metastasis) by mHSPC indication
Tijdsspanne: Up to 52 weeks

Radiological progression is defined as the time (months) from the start of Darolutamide treatment to the date of first documentation of radiological progressive disease or death due to any cause, whichever occurs first.

Up to 52 weeks
Radiological Progression-Free Survival (rPFS) by mHSPC indication
Tijdsspanne: Up to 52 weeks

Radiographic Progression-Free Survival (rPFS) is defined as the time (months) from the initiation of Darolutamide treatment to the date of the first radiologically confirmed disease progression or death from any cause, whichever occurs first.

Up to 52 weeks
Duration of Darolutamide treatment
Tijdsspanne: Up to 52 weeks

Duration of Darolutamide treatment is defined as the time (months) from the start of Darolutamide treatment to the day of permanent discontinuation of Darolutamide (including death).

Up to 52 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

25 september 2024

Primaire voltooiing (Geschat)

31 maart 2028

Studie voltooiing (Geschat)

30 juni 2028

Studieregistratiedata

Eerst ingediend

21 maart 2024

Eerst ingediend dat voldeed aan de QC-criteria

21 maart 2024

Eerst geplaatst (Werkelijk)

27 maart 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

5 november 2026

Laatste update ingediend die voldeed aan QC-criteria

4 november 2026

Laatst geverifieerd

4 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 20654

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren